Lusutrombopag
Lusutrombopag is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist. It acts selectively on the human TPO receptor and activates signal transduction pathways and thereby increases platelet levels. It was developed by Shionogi for chronic liver disease (CLD) patients with thrombocytopenia prior to elective invasive surgery. It has been listed.
| Catalog Number | API1110766976 |
| Alternative Name(s) | mulpleta S-888711 (S,E)-3-(2,6-Dichloro-4-((4-(3-(1-(hexyloxy)ethyl)-2-methoxyphenyl)thiazol-2-yl)carbamoyl)phenyl)-2-methylacrylic acid |
| Research Area | Platelet-Promoting APIs |
| Molecular Formula | C29H32Cl2N2O5S |
| CAS# | 1110766-97-6 |
| SMILES | CCCCCCOC(C)C1=CC=CC(=C1OC)C2=CSC(=N2)NC(=O)C3=CC(=C(C(=C3)Cl)C=C(C)C(=O)O)Cl |
| Size | inquiry |
| Supplier Page | https://www.protheragen-ing.com/lusutrombopag-item-12520.html |